ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

MRNA Moderna Inc

108.85
0.96 (0.89%)
Apr 24 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 3,410,217
Bid Price 108.82
Ask Price 108.97
News -
Day High 111.29

Low
62.55

52 Week Range

High
142.79

Day Low 106.66
Company Name Stock Ticker Symbol Market Type
Moderna Inc MRNA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.96 0.89% 108.85 19:59:28
Open Price Low Price High Price Close Price Prev Close
111.05 106.66 111.29 108.85 107.89
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
51,616 3,410,217 $ 108.33 $ 369,441,494 - 62.55 - 142.79
Last Trade Time Type Quantity Stock Price Currency
19:59:59 25 $ 108.82 USD

Moderna (MRNA) Options Flow Summary

Overall Flow

Bearish

Net Premium

-525k

Calls / Puts

77.46%

Buys / Sells

95.31%

OTM / ITM

96.88%

Sweeps Ratio

0.02%

Moderna Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
41.59B 382.07M - 6.85B -4.71B -12.34 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Moderna News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No MRNA Message Board. Create One! See More Posts on MRNA Message Board See More Message Board Posts

Historical MRNA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week104.51111.2999.30103.942,415,1124.344.15%
1 Month109.60115.8997.00105.873,216,111-0.75-0.68%
3 Months102.47115.8984.06100.443,839,8206.386.23%
6 Months78.81115.9762.5593.384,440,73130.0438.12%
1 Year140.79142.7962.55102.844,039,024-31.94-22.69%
3 Years171.79497.1762.55219.706,993,383-62.94-36.64%
5 Years24.80497.1711.54147.558,791,59584.05338.91%

Moderna Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 44 mRNA development programs as of early 2022, with 25 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

Your Recent History

Delayed Upgrade Clock